Zydus Lifesciences receives USFDA tentative approval for Diroximel Fumarate Delayed-Release Capsules
Zydus Lifesciences has received tentative approval from the United States Food and Drug Administration (USFDA) to market Diroximel Fumarate Delayed-Release Capsules, 231 mg (USRLD: Vumerity Delayed-Release Capsulestablets).